Category: Stock Market

Liontown Ltd (ASX: LTR) shares are under pressure on Thursday morning.

At the time of writing, the lithium miner’s shares are down 2.5% to $1.59.

Why are Liontown shares falling?

Investors have been selling Liontown shares this morning following the release of its half-year results.

According to the release, the company delivered strong growth in production and revenue during the half as the Kathleen Valley lithium project ramps up underground operations.

For the six months ended 31 December, Liontown produced 192,514 dry metric tonnes (dmt) of spodumene concentrate at a grade of 5.0% Li₂O. This represents a 70% increase on the prior corresponding period.

Sales volumes also surged, rising 106% to 189,596 dmt as the Kathleen Valley operation increased output.

Liontown’s average realised price for the period was US$888 per dmt for SC6 concentrate. This is up from US$811 per dmt a year earlier. This helped drive revenue of $207.5 million for the half year, more than double the $100.4 million recorded in the prior corresponding period.

The good news is that its realised price is likely to rise further in the coming quarter. Liontown highlighted that its inaugural Metalshub spot auction in November 2025 cleared at US$1,254 per dmt SC6 for shipment in January 2026.

Ramp-up weighs on earnings

Despite the strong growth in production and revenue, Liontown reported an underlying EBITDA loss of $7.7 million as the project continues to ramp up production.

The company also posted a statutory net loss after tax of $184 million. However, this includes $104.4 million of non-cash charges relating to the LGES convertible note derivative.

Management advised that this accounting charge was largely driven by the company’s share price appreciation during the period and will not recur following the conversion of the LGES notes to equity in February 2026.

Operational costs also declined through the half, with unit operating costs of $985 per dmt and all-in sustaining costs of $1,179 per dmt.

Outlook

Liontown’s managing director and CEO, Tony Ottaviano, was pleased with the half and is positive on its outlook. He said:

Kathleen Valley is now a 100% underground operation. We have delivered a one million tonne per annum underground run-rate on schedule, sold 190,000 tonnes of concentrate across ten shipments, and more than doubled revenue period to period. The underground ramp-up is on track and we expect the second half to be materially stronger as volumes, recoveries, and pricing all continue to improve.

The company’s FY 2026 guidance remains unchanged and cash generation is expected to improve through the second half as production continues to ramp up.

The company also confirmed that work is underway on a refresh of its planned 4 million tonne per annum expansion at the Kathleen Valley lithium operation.

The post Liontown shares drop on $184m half-year loss appeared first on The Motley Fool Australia.

More reading

• Liontown: Production and revenue jump as underground ramp-up continues
• Australia’s next great ASX mining boom: Are we already in it?
• ASX 200 materials sector leads as earnings season ends with a record high
• Why these 3 ASX lithium shares are charging higher today
• Here are the top 10 ASX 200 shares today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Liontown Ltd (ASX: LTR) share price is in focus after the lithium miner reported a 70% jump in production to 192,514 dmt and more than doubled half-year revenue to $207.5 million.

What did Liontown report?

• Production: 192,514 dmt at 5.0% Li₂O (up 70% year-on-year); sales 189,596 dmt (up 106%)
• Revenue: $207.5 million, up 107% from H1 FY2025
• Underlying EBITDA: $(7.7) million, reflecting ramp-up costs
• Statutory loss after tax: $(184.0) million, driven by a one-off $(104.4) million non-cash charge
• Unit operating cost: A$985/dmt (FOB); all-in sustaining cost A$1,179/dmt (FOB)
• Cash balance: $390.5 million at 31 December 2025

What else do investors need to know?

The transition to 100% underground mining at Kathleen Valley has been completed, with operational targets achieved on schedule. Liontown reached a run-rate of 1 million tonnes per annum and is targeting 1.5 Mtpa by the end of March 2026.

Liontown’s balance sheet has been reshaped following the conversion of convertible notes held by LG Energy Solution to equity, reducing pro forma gearing (excluding leases) from 48% to 22%. The company also amended its loan facility with Ford, deferring repayments by 12 months to September 2026.

A 4 million tonne per annum expansion study is underway, aiming to leverage existing infrastructure and capitalise on favourable market trends.

What did Liontown management say?

Liontown’s Managing Director and CEO, Tony Ottaviano, said:

Kathleen Valley is now a 100% underground operation. We have delivered a one million tonne per annum underground run-rate on schedule, sold 190,000 tonnes of concentrate across ten shipments, and more than doubled revenue period to period. The underground ramp-up is on track and we expect the second half to be materially stronger as volumes, recoveries, and pricing all continue to improve.

What’s next for Liontown?

The company is expecting a stronger second half in FY2026 as higher volumes, improving recoveries, and rising lithium prices flow through. Guidance for unit costs and production remains unchanged.

Liontown is actively progressing the 4 Mtpa brownfield expansion study, aiming to position itself as one of the very few producers able to bring additional tonnes to the lithium market quickly. The refreshed balance sheet and deferred debt repayments provide a foundation for both ongoing ramp-up and future growth.

Liontown share price snapshot

Over the past 12 months, Liontown shares have risen 167%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 12% over the same period.

View Original Announcement

The post Liontown: Production and revenue jump as underground ramp-up continues appeared first on The Motley Fool Australia.

More reading

• Champion Iron secures 90% acceptance for Rana Gruber takeover
• Contact Energy reports strong support for 2026 retail share offer
• 5 things to watch on the ASX 200 on Thursday
• Here are the top 10 ASX 200 shares today
• GQG Partners lifts FUM to US$172.9bn in February 2026

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Australian share market has no shortage of quality ASX growth shares. But after the recent tech pullback, several sector leaders are trading well below their previous highs — creating what could be compelling long-term opportunities.

If I had $10,000 to invest today, I’d focus on three businesses that dominate their respective niches: healthcare imaging, cloud accounting software, and buy now, pay later (BNPL) payments.

Each ASX growth share has proven technology, strong growth prospects, and significant global expansion potential. While their share prices have all tumbled by 50% or more over the past 6 months, the underlying businesses continue to grow.

Here are three ASX growth shares I’d consider buying today.

Pro Medicus Ltd (ASX: PME)

This $22 billion ASX growth share has become one of the most successful technology companies listed on the Australian market. The Melbourne-based business develops advanced medical imaging software used by hospitals and healthcare providers to process and analyse radiology scans.

Its flagship Visage platform is widely regarded as one of the most powerful imaging systems available. It allows doctors to view and interpret medical images rapidly through cloud-based infrastructure.

A key strength of the business is its highly scalable software model. As new hospitals adopt the platform, the company can grow revenue without significantly increasing costs. This has resulted in exceptional profitability, with operating margins among the highest of any ASX technology company.

The main risk for investors is valuation. The ASX growth share has historically traded at premium multiples, and the company’s growth expectations remain high. Any slowdown in contract wins could weigh on sentiment.

Even so, analysts remain broadly positive. The average 12-month price target is $218.44, representing a potential 60% upside from the current price of $136.79.

Xero Ltd (ASX: XRO)

Xero is one of the world’s leading cloud accounting platforms for small businesses. Founded in New Zealand, the company now serves millions of subscribers across Australia, the United Kingdom, and the US.

Xero has built a powerful ecosystem that connects small businesses with accountants, banks, and payment providers. This network effect makes the platform increasingly valuable as more users join.

Despite strong operational performance in recent years, the share price has experienced volatility amid the broader technology sector sell-off.

The main risks revolve around competition and execution. Xero is expanding aggressively into the US, which represents a massive opportunity but also a highly competitive market.

Most analysts remain optimistic on the ASX growth share and have set an average price target of $152.48, which suggests a possible gain of 86% over 12 months.

Zip Co Ltd (ASX: ZIP)

This ASX growth share has undergone a dramatic transformation over the past few years. Once one of the most speculative names in the buy now, pay later sector, the company has shifted its focus toward profitability and financial discipline.

That strategy appears to be paying off. The company has reported improving margins and stronger cash earnings, while transaction volumes continue to grow in its core markets.

The long-term opportunity remains significant. Digital payments and flexible financing options are becoming increasingly popular among consumers, and Zip’s platform enables shoppers to spread purchases over time while boosting merchants’ conversion rates.

However, risks remain. The buy now, pay later sector is highly competitive, and consumer credit conditions can deteriorate during economic downturns.

Even so, several analysts see improving fundamentals and potential upside for the ASX growth share if the company continues executing its turnaround strategy.

Most brokers have a buy rating on Zip and have set a 12-month price target of $4.21. This points to a massive 146% increase at the current share price of $1.71.

The post Where I’d invest $10,000 in ASX growth shares right now appeared first on The Motley Fool Australia.

More reading

• 3 of the best ASX 200 shares to buy and hold forever
• What I’d do as a beginner with $50,000 to invest in ASX shares
• Top brokers name 3 ASX shares to buy today
• Macquarie says this major fintech stock can rocket almost 100%
• Forget Xero shares, this ASX tech stock is tipped to double in value

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

ASX healthcare stocks have largely struggled over the last 12 months. 

The S&P/ASX 200 Health Care Index (ASX: XHJ) is down more than 20% in that span. 

The sector has struggled to break out of its multi-year downgrade cycle, weighed down by negative consensus earnings revisions from index heavyweights. 

However, there are now buy-low opportunities according to experts. 

In a recent report, Canaccord Genuity said this backdrop presents an attractive risk/reward for the sector. 

“After a challenging period for Healthcare returns, valuations across the sector have become increasingly attractive. At the index level, the ASX 100 Healthcare sector now trades at two-decade lows on a relative P/E basis.”

Here are two ASX healthcare shares with big upside according to brokers. 

Anteris Technologies Global Corp (ASX: AVR)

Anteris Technologies is a structural heart company. It researches, develops, commercialises, and distributes various medical technologies and devices. 

It manufactures, distributes, and sells ADAPT & DurAVR regenerative tissue products, and researches and develops regenerative medicine and immunotherapies.

This ASX healthcare stock is down more than 19% over the last 12 months, but has begun to recover from yearly lows. 

Recently, Bell Potter raised its price target to $13 (from $10), along with retaining a speculative buy rating. 

The broker has optimism around its future thanks to progress in getting its DurAVR product approved. 

The product uses a single-piece, native-shaped biomimetic design built to mimic the performance of a healthy aortic valve.

Based on yesterday’s closing price of $8.86, this Bell Potter price target indicates potential upside of almost 47%. 

Telix Pharmaceuticals Ltd (ASX: TLX)

Another ASX healthcare stock tipped to recover is Telix Pharmaceuticals. 

It is a commercial-stage biopharmaceutical company focused on the ongoing development of diagnostic and therapeutic (‘theranostic’) products using targeted radiation.

Its share price has fallen almost 60% over the last year; however, experts are anticipating a bounce back. 

A key announcement earlier this week saw the ASX healthcare stock price jump considerably, which could be the beginning of a long-term recovery. 

On Monday, the share price rocketed 9% higher after the company released encouraging Part 1 results from its global Phase 3 ProstACT study of TLX591-Tx, its novel prostate cancer therapy. 

Results showed the therapy demonstrated an acceptable and manageable safety profile, with no new safety signals and sustained tumour uptake across patients.

The team at Jarden currently have a $21 price target on Telix shares.

Meanwhile, Morgan Stanley has a $24.60 price target. 

Based on yesterday’s closing price of $10.76, these targets indicate an upside of 95% to 129%. 

The post Should you buy low on these ASX healthcare stocks? appeared first on The Motley Fool Australia.

More reading

• This drug developer could have huge upside, brokers say
• Four ASX healthcare stocks which are looking cheap
• Here are the top 10 ASX 200 shares today
• Why Life360, St George Mining, Telix, and Westgold shares are charging higher today
• Telix shares jump 14% on big news

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Champion Iron Ltd (ASX: CIA) share price is in focus today after the company announced it has satisfied the minimum shareholder acceptance condition for its voluntary cash offer to acquire Rana Gruber. Champion now holds acceptances representing approximately 90.07% of Rana Gruber shares, paving the way for potential full ownership pending final conditions.

What did Champion Iron report?

• Champion Iron’s voluntary cash offer for Rana Gruber reached minimum acceptance, with 90.07% of shares tendered.
• The offer price is NOK 79 per Rana Gruber share.
• Champion Iron may acquire all remaining shares via compulsory acquisition under Norwegian law after completion.
• Completion of the offer remains subject to other closing conditions.
• Champion Iron operates the Bloom Lake Mining Complex and holds multiple strategic iron ore assets.

What else do investors need to know?

Champion Iron’s acceptance milestone means it is set to acquire a controlling stake in Rana Gruber, a move that could reshape its position in the high-grade iron ore segment. The company intends to carry out a compulsory acquisition of the remaining shares once all conditions are fulfilled.

This deal builds on Champion’s established presence in Québec’s iron ore industry, with assets like Bloom Lake and a 51% interest in the Kami Project, highlighting its continued growth in premium iron ore products. Investors should note that completion still hinges on other customary closing conditions.

What’s next for Champion Iron?

Assuming all closing conditions are met, Champion Iron aims to finalise the acquisition and integrate Rana Gruber into its operations. The company signalled plans to undertake a compulsory acquisition of any remaining shares under Norwegian law.

Champion’s broader strategy remains focused on high-grade, low-contaminant iron ore production, investing to upgrade and expand its processing capacity. Investors can expect continued focus on operational growth and international market reach.

Champion Iron share price snapshot

Over the past 12 months, Champion Iron shares have declined 1%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 12% over the same period.

View Original Announcement

The post Champion Iron secures 90% acceptance for Rana Gruber takeover appeared first on The Motley Fool Australia.

More reading

• Liontown: Production and revenue jump as underground ramp-up continues
• Contact Energy reports strong support for 2026 retail share offer
• 5 things to watch on the ASX 200 on Thursday
• Here are the top 10 ASX 200 shares today
• GQG Partners lifts FUM to US$172.9bn in February 2026

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The Contact Energy Ltd (ASX: CEN) share price is in focus after the company’s retail share offer closed oversubscribed, with around NZ$251 million in applications and strong shareholder demand.

What did Contact Energy report?

• Retail share offer oversubscribed, receiving approximately NZ$251 million in valid applications
• 29,727 eligible shareholders participated, up from 18,667 in the 2021 offer
• Total NZ$125 million raised under the retail offer after accepting an additional NZ$50 million in oversubscriptions
• Retail offer shares issued at NZ$8.75 per share (A$7.36 for Australian investors)
• Settlement and trading to commence on NZX from 13 March 2026, and on ASX from 16 March 2026
• Dividend Reinvestment Plan (DRP) strike price set at NZ$8.75, with shares issued 25 March 2026

What else do investors need to know?

The retail offer is part of Contact’s broader capital raising effort, following a fully underwritten NZ$450 million institutional placement. The total equity raise aims to support the acceleration and potential expansion of Contact’s renewable energy projects, in line with its Contact31+ strategy.

Participation in the retail offer was notably strong, with more shareholders taking part than in previous rounds. All new shares will rank equally with existing ordinary shares, and confirmations on allocations and any surplus refunds will be sent out from 19 March 2026.

The Dividend Reinvestment Plan’s strike price has also been set to benefit investors, using the lower of the five-day volume weighted average price (less a 2% discount) or NZ$8.75, which aligns with the retail offer price.

What’s next for Contact Energy?

Proceeds from the capital raising will be directed towards advancing and potentially upsizing renewable energy developments. These projects are designed to boost Contact’s environmental credentials and future growth as part of its Contact31+ strategic goals.

Investors should watch for further announcements as new projects take shape and the company provides updates on deployment and impacts on future earnings.

Contact Energy share price snapshot

Over the past 12 moths, Contact energy shares have declined 4%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 12% over the same period.

View Original Announcement

The post Contact Energy reports strong support for 2026 retail share offer appeared first on The Motley Fool Australia.

More reading

• Liontown: Production and revenue jump as underground ramp-up continues
• Champion Iron secures 90% acceptance for Rana Gruber takeover
• 5 things to watch on the ASX 200 on Thursday
• Here are the top 10 ASX 200 shares today
• GQG Partners lifts FUM to US$172.9bn in February 2026

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

I’ve warned before about falling victim to the superannuation myths which could eat away at your balance and derail your retirement. But what about the secret tips to grow it?

Here are 10 lesser-known ways to boost your superannuation balance to get the most out of your retirement. 

1. Fiddle with your insurance

This isn’t a suggestion to cancel your insurance, but make sure to double check your cover is necessary and the premiums are appropriate for you. Many super funds include insurance but there is no point paying for cover that is far too high. 

2. Take advantage of catch-up concessional contributions

The current concessional contributions cap is $30,000 per financial year. If you contribute less than the before-tax cap in one financial year, the leftover amount gets carried into the next year. In fact, you can carry over your leftover pre-tax cap amounts from the past five years, which means you can make larger contributions above the $30,000 limit without the extra tax. 

3. Use the downsizer contributions rule

Australians aged 55 or above can contribute up to $300,000 from the proceeds of the sale (or part sale) of their property into their complying superannuation fund. This is called a downsizer contribution, and it does not count towards contribution caps. It’s an easy way to boost your balance if you’re planning to sell up.

4. See if you’re eligible for the bring-forward rule

This is similar to the catch-up concessional contribution, but the bring-forward rule applies to after-tax (i.e non-concessional) contributions. Under this rule, eligible Australians can contribute three years’ worth of non-concessional contributions (up to $120,000 per year) at once.

5. Find out about the government co-contribution scheme

Low- and middle-income Australians might be eligible for a government co-contribution if they make after-tax contributions to super. This means you’d be, effectively, boosting your balance with extra government funds.

6. Claim a tax deduction on personal contributions

Many Australians aren’t aware that they can make extra contributions to their superannuation fund and then claim it as a tax deduction. This is a double win. It boosts your superannuation balance and reduces your taxable income at the same time. 

7. Ask your spouse to add extra

Couples can boost their combined super savings by the higher-income earner contributing after-tax funds to the lower-income earner’s account. If your spouse earns less than $40,000 per year, it might even earn you a tax offset.

8. Consolidate your funds

Ok, so this one is actually something the experts will tell you to do. In fact, they say it time and time again. By having multiple superfund accounts across several providers, not only will you struggle to keep hold of how much you actually have, but you’re also paying duplicate fees and insurance premiums. Consolidating accounts into one fund can help reduce costs and increase your final balance.

9. Check for lost super

As I mentioned above, if you have multiple accounts across multiple funds, it’s easy to lose track of your total superannuation balance. In fact, it’s easy to lose one of your accounts altogether. Check that all your superannuation is accounted for. Recovering lost funds will instantly boost your balance.

10. Review your risk appetite

Most superfunds default to a ‘balanced’ option, but it doesn’t need to stay that way. You can change your risk level to something that might work better for you. After all, if a fund even slightly underperforms a benchmark, such as the S&P/ASX 200 Index (ASX: XJO), over a long period of time, it can seriously dent your end balance.

The post 10 hacks to boost your superannuation (that the experts won’t tell you) appeared first on The Motley Fool Australia.

More reading

• Liontown: Production and revenue jump as underground ramp-up continues
• Where I’d invest $10,000 in ASX growth shares right now
• Should you buy low on these ASX healthcare stocks?
• Champion Iron secures 90% acceptance for Rana Gruber takeover
• Contact Energy reports strong support for 2026 retail share offer

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Life360 Inc (ASX: 360) shares closed 4.84% lower on Wednesday afternoon, wiping out half the gains made the day before.

The US-based software development company’s shares are now 61.36% below an all-time high of $55.87 recorded in October last year. The stock has crashed 34.01% year to date but is 0.19% above its value 12 months ago.

So, if I bought $10,000 worth of Life360 shares at the beginning of March, what are they worth now?

It’s been a turbulent start to the month for Life360 shares.

The stock crashed 18% on Tuesday last week after it posted its FY25 financial results. 

The company delivered record growth in both its subscription and international segments, by 33% and 26% year-on-year, respectively. Life360 also said that it expects strong growth to continue in FY26. 

The news sent investors flocking to the stock, with the share price spiking 15% in early-morning trade shortly after the announcement. But then the share price took a significant U-turn, ending the day down 18%.

This week, the share price took another turn, jumping over 10% on Tuesday. 

There has been no price-sensitive news out of the company following its results announcement, so the zig-zagging share price is likely due to investors taking their gains off the table and then buying back into the stock after the dust had settled.

It has been difficult to keep track of Life360 shares over the past couple of weeks. But yesterday’s 4.84% drop means the stock is now 12.82% lower than at the beginning of March.

That means that $10,000 invested in Life360 shares at the start of March has already lost value, now worth just $8,718.

Meanwhile, $10,000 invested in Life360 shares this time last year would now be worth $10,019.

Should investors sell up before losses worsen? 

Analysts don’t think so. In fact, it looks like the current share price could be a once-in-a-lifetime opportunity to buy into Life360 shares cheaply. Because if analyst predictions are correct, the tech stock could soar higher this year.

TradingView data shows that most analysts are extremely bullish on Life360’s shares over the next 12 months. 

Out of 15 analysts, 12 have a buy or strong buy rating, and three have a hold rating on the stock. 

The average target price for Life360 shares is $39.82, implying a huge potential 85.9% upside at the time of writing. But some are even more bullish, expecting the stock to rocket 137.81% to $50.94 apiece over the next 12 months.

With these types of returns, $10,000 invested at the start of March could be worth up to $23,781 by this time next year.

The post $10,000 invested in Life360 shares at the start of March is now worth… appeared first on The Motley Fool Australia.

More reading

• Are 4DMedical and Life360 shares a buy, hold or sell after rocketing 10% yesterday?
• 4 ASX tech shares tipped to jump up to 140% higher
• Here are the top 10 ASX 200 shares today
• 3 ASX shares to buy for magnificent long-term growth
• 3 ASX tech stocks that brokers rate as buys

Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Life360. The Motley Fool Australia has positions in and has recommended Life360. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

With markets swinging significantly over the past week, it can be a challenge not to overreact. 

At the time of writing, the S&P/ASX 200 Index (ASX: XJO) is down 5% and the S&P 500 Index (SP: .INX) is down nearly 2% just since the beginning of March. 

Watching your portfolio plummet can induce panic. 

However it’s at times like these investors need to remain focussed on the long-term. 

Research from Betashares reinforced the importance of this discipline. 

Hans Lee, Senior Finance Writer at BetaShares said price swings and permanent losses are not the same thing. 

What often separates the two is whether an individual stayed invested long enough for the market to do its job.

During the Liberation Day sell-down, a hypothetical investor who sold right at the top and reinvested just 3 months later would have underperformed an investor who ‘rode out’ the crash without selling by more than 8% in less than a year.

In other words, remaining invested would have resulted in better returns.

For those investors focussed on holding through the volatility, here are three ASX ETFs that have risen steadily over the long term. 

BetaShares Australia 200 ETF (ASX: A200)

Put simply, this ASX ETF aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

The fund includes blue-chip companies like the big four banks, as well as mining and materials giants. 

It is a popular option for investors looking for simple exposure to the ASX 200. 

Furthermore, it has a strong track record, with a per annum return of 10.97% over the last 5 years. 

Vanguard MSCI Index International Shares ETF (ASX: VGS)

A nice compliment to an Australian focussed ASX ETF is this fund from Vanguard. 

It includes around 1,300 companies from developed countries, excluding Australia.

Investing internationally offers greater access to sectors such as technology and health care that aren’t as well represented in the Australian share market.

It has brought annual returns of almost 15% over the last 5 years. 

Vanguard S&P 500 US Shares Index ETF (ASX: V500)

This fund from Vanguard is actually brand new. 

It only hit the market last week. 

However, the fund provides exposure to a diversified portfolio of the 500 largest publicly listed U.S. companies across all major sectors. 

While the fund is new, the index it tracks – the S&P 500 – is one of the benchmark US indexes. 

The index is up 71.19% over the last 5 years. 

The post Look long-term with these 3 ASX ETFs appeared first on The Motley Fool Australia.

More reading

• Just 3 ASX ETFs could build a lazy Australian millionaire portfolio
• 3 perfect ASX ETFs for beginner investors in 2026
• I would put $10,000 into these Vanguard ETFs tomorrow if I could
• How investing $50 a day into ASX shares could become $1 million faster than you think
• 4 ASX ETFs to ride through recessions and market crashes

Motley Fool contributor Aaron Bell has positions in Vanguard Msci Index International Shares ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Vanguard Msci Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

There are always ASX share opportunities to be found given how share prices and earnings are regularly changing. Experts recently called two particular businesses a buy after considering their latest developments and updates.

When experts call a business a buy, it’s worth taking note because of the positive outlook that the analysts have identified for the business(es).

The two stocks I’m going to highlight are both from outside the tech industry. Accordingly, they could have clearer growth outlooks than others because they’re not as exposed to possible AI impacts. Let’s take a look at why the ASX shares are buy-rated by UBS.

GQG Partners Inc (ASX: GQG)

UBS describes GQG as a boutique active asset manager that specialises in managing global shares. The business has a track record of strong performance over most of its life and it also provides funds for a relatively low cost.

The broker said that the month of February 2026 saw a record high funds under management (FUM) which was a 4.3% month-over-month increase, driven by investment returns. However, it continued to experience elevated net outflows of US$3.2 billion, though lower than UBS was expecting of US$3.7 billion.

There was an improvement in US equity outflows, with that strategy experiencing a sharp improvement in performance in US equities flows. This suggests that this rebound could lead to a relatively quick turnaround in outflows.

However, the emerging market strategy, where underperformance has been deepest, continues to be a headwind with outflows for the ASX share.

Pleasingly, early March has seen outperformance by GQG’s strategies. UBS then explained why it rates GQG as a buy with a price target of $2:

We continue to see GQG as an attractive market-hedge, and a relative performance beneficiary of the current backdrop given its defensive portfolio tilts.

Orica Ltd (ASX: ORI)

UBS describes Orica as the world’s largest supplier of commercial explosives and blasting systems servicing both the mining and infrastructure sectors. The broker also noted that the business manufactures ammonium nitrate (AN) from its plants in Australia, North America and Indonesia.

UBS recently released a note highlighting that the ASX share released a trading update which included expectations that the FY26 first half operating profit (EBIT) will be slightly higher than the prior corresponding period of A$493 million. That expectation is “broadly consistent” with the average forecast of market analysts (consensus) of A$493 million.

However, Orica expects blasting solutions EBIT to be lower year over year because of foreign exchange rates and lower Indonesian coal demand. Digital solutions and specialty mining chemicals are supposedly on track to deliver EBIT growth of 20% and 15%, respectively, year-over-year thanks to strong gold and copper exploration and production demand.

UBS is forecasting that Orica’s FY26 EBIT could grow by 2% despite the foreign exchange and Indonesian demand headwinds. The broker said:

We retain our Buy rating with the stock offering a 3yr EPS CAGR of 8% (FY25-28E) linked to resilient global mine production activity, and supportive AN prices given potentially tightening global supply. UBS rates Orica as a buy with a price target of $27.

The post 2 compelling ASX shares experts rate as buys in March appeared first on The Motley Fool Australia.

More reading

• Why Breville, Forrestania Resources, GQG Partners, and WiseTech shares are falling today
• Why this ASX 200 financials stock is crashing 7.6% today
• Buy this ASX 200 share benefiting from ‘cyclical tailwinds’: Top broker
• GQG Partners lifts FUM to US$172.9bn in February 2026
• Guess which ASX 200 share is storming higher on business update

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Gqg Partners. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.